<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tranexamic Acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00302</strong>&#160; (APRD01270, EXPT00508)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Antifibrinolytic hemostatic used in severe hemorrhage. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00302/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00302/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00302.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00302.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00302.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00302.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00302.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00302">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Tranexamsaeure</td><td>German</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tranexmic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tranhexamic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trans AMCHA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>trans-4-aminomethylcyclohexane-1-carboxylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>trans-Amcha</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>trans-Tranexamic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cyclo-F</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cyklokapron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Espercil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Femstrual</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lysteda</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rikavarin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Transamin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Transcam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Traxyl</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antifibrinolytic-agents">Antifibrinolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>1197-18-8</td></tr><tr><th>Weight</th><td>Average: 157.2102<br>Monoisotopic: 157.110278729</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>GYDJEQRTZSCIOI-LJGSYFOKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC[C@H]1CC[C@@H](CC1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Polyamines</td></tr><tr><th>Direct parent</th><td>Polyamines</td></tr><tr><th>Alternative parents</th><td>Carboxylic Acids; Enolates; Monoalkylamines</td></tr><tr><th>Substituents</th><td>primary aliphatic amine; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the polyamines. These are compounds containing more than one amine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.</td></tr><tr><th>Pharmacodynamics</th><td>Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).</td></tr><tr><th>Mechanism of action</th><td>Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.</td></tr><tr><th>Absorption</th><td>Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>9 to 12 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Only a small fraction of the drug is metabolized (less than 5%).</p></td></tr><tr><th>Route of elimination</th><td>Urinary excretion is the main route of elimination via glomerular filtration.</td></tr><tr><th>Half life</th><td>Biological half-life in the joint fluid is about 3 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>110 &#8211; 116 mL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> in mice is &gt;10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Tranexamic Acid Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9538</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8672</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7572</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9915</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8475</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7446</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8862</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.829</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9504</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9577</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9452</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9313</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9698</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8916
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8495
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6921
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.0517 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8797
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9156
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li>
<li>Ferring pharmaceuticals as</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.gallipot.com">Gallipot</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.pccarx.com">Professional Compounding Centers America LLC</a></li>
<li><a href="http://www.xanodyne.com">Xanodyne Pharmaceuticals Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>